Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Livzon Pharma to Spend $154 Million on New API Facilities

publication date: Jun 1, 2011
Livzon Pharma plans to invest one billion RMB ($154 million) to build two new fabrication facilities in a Ningxia Hui Autonomous Region industrial park. As a first step, Livzon will allocate 90 million RMB apiece to form two JVs, each of which will be formed with one of its subsidiaries. The JVs will increase production of each subsidiary’s APIs. First phase work in the park will cost 300 million RMB ($46 million). More details....

Stock Symbol: (SHE: 200513)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital